ORGARAN

This brand name is authorized in Austria, Canada, Finland, France, Ireland, Japan, Netherlands

Active ingredients

The drug ORGARAN contains one active pharmaceutical ingredient (API):

1 Danaparoid UNII 5004UU3156 - DANAPAROID SODIUM

Danaparoid has been shown both in animal models and in human studies to be an effective antithrombotic substance. At therapeutic doses danaparoid has no or only a minor effect on haemostatic plug formation, platelet function and platelet aggregability with no significant effect on bleeding time at the recommended doses. Read about Danaparoid

Medication package inserts

Below package inserts are available for further reading:

Title	Information Source	Document Type
Orgaran	Medicines & Healthcare Products Regulatory Agency (GB)	MPI, EU: SmPC

Medicine classification

This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:

ATC code	Group title	Classification
B01AB09	Danaparoid	B Blood and blood forming organs → B01 Antithrombotic agents → B01A Antithrombotic agents → B01AB Heparin group
Discover more medicines within B01AB09

Authorization and marketing

This drug has been assigned below unique identifiers within the countries it is being marketed:

Country	Identification scheme	Identifier(s)
Country: CA	Health Products and Food Branch	Identifier(s): 02129043
Country: FI	Lääkealan turvallisuus- ja kehittämiskeskus	Identifier(s): 052951
Country: FR	Base de données publique des médicaments	Identifier(s): 69449143
Country: JP	医薬品医療機器総合機構	Identifier(s): 3339600A1030
Country: NL	Z-Index G-Standaard	Identifier(s): 13888285
Country: NL	Z-Index G-Standaard, PRK	Identifier(s): 34339